Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest announcement is out from Merit Medical Systems ( (MMSI) ).
On November 3, 2025, Merit Medical Systems completed the acquisition of the C2 CryoBalloon device and related technology from Pentax of America, Inc. This strategic acquisition is expected to enhance Merit’s product portfolio and strengthen its position in the medical device market, although it involves substantial risks and uncertainties regarding integration and financial performance.
The most recent analyst rating on (MMSI) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Merit Medical Systems stock, see the MMSI Stock Forecast page.
Spark’s Take on MMSI Stock
According to Spark, TipRanks’ AI Analyst, MMSI is a Outperform.
Merit Medical Systems’ overall stock score is driven by its strong financial performance and positive earnings call, highlighting robust revenue growth and strategic initiatives. However, the high P/E ratio suggests overvaluation, and technical indicators point to potential resistance in the long term.
To see Spark’s full report on MMSI stock, click here.
More about Merit Medical Systems
Merit Medical Systems, Inc. operates in the medical device industry, focusing on the development and manufacturing of products for interventional and diagnostic procedures. The company is known for its innovative medical technologies and solutions, catering to healthcare professionals and patients worldwide.
Average Trading Volume: 583,291
Technical Sentiment Signal: Hold
Current Market Cap: $5.19B
See more insights into MMSI stock on TipRanks’ Stock Analysis page.